SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-010231
Filing Date
2022-03-15
Accepted
2022-03-15 08:08:52
Documents
14
Period of Report
2022-03-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cogt-8k_20220315.htm   iXBRL 8-K 47097
2 EX-99.1 cogt-ex991_38.htm EX-99.1 185321
3 GRAPHIC gmivro21vqit000001.jpg GRAPHIC 78233
  Complete submission text file 0001564590-22-010231.txt   486557

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA cogt-20220315.xsd EX-101.SCH 5697
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE cogt-20220315_lab.xml EX-101.LAB 20173
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cogt-20220315_pre.xml EX-101.PRE 12037
8 EXTRACTED XBRL INSTANCE DOCUMENT cogt-8k_20220315_htm.xml XML 3679
Mailing Address 200 CAMBRIDGE PARK DRIVE SUITE 3100 CAMBRIDGE MA 02140
Business Address 200 CAMBRIDGE PARK DRIVE SUITE 3100 CAMBRIDGE MA 02140 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

IRS No.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38443 | Film No.: 22739175
SIC: 2834 Pharmaceutical Preparations